Status: Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Participants needed: 600
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Panbela Therapeutics, Inc.Updated: Nov 6, 2024Locations: 93
Eligibility criteria
Histologically or cytologically confirmed metastatic pancreatic ductal adenocarc... [+9]
When results of germline or somatic testing done prior to screening are known, s... [+17]